The pathogenic mutations in smokers with non-small cell lung cancer: a next-generation sequencing study.

ABSTRACT:

Background

Tyrosine kinase inhibitor (TKI)-targeted therapy has significantly improved the quality life of patients with advanced non-small cell lung cancer (NSCLC). Smoking is the main pathogenic factor of lung cancer. A number of the studies have analyzed smoking patients and nonsmoking patients as grouping factors, but few have examined the characteristic gene mutations in these groups. This study thus aimed to examine the characteristic pathogenic mutations in smokers with NSCLC.

Methods

A total of 302 smokers with stage IIIB-IV NSCLC were recruited from Jilin Cancer Hospital between June 2022 and July 2024. Gene sequencing was performed on tumor tissues, pleural effusion cells, and plasma via next-generation sequencing (NGS).

Results

A total of 302 smoking patien

SUBMITTER: Yan S 

PROVIDER: S-EPMC12541858 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature